Precision Diagnostics Growth MedGenome’s expanding test menu with over 1,300 genetic assays across rare inherited disorders, oncology, reproductive health, infectious diseases and preventive wellness indicates strong opportunities to upsell comprehensive genomic panels to existing hospital networks and clinics seeking integrated diagnostic workflows.

Strategic Partnerships Recent investments and majority stakes in Green Cross Genetics Lab and Greencrosslab demonstrate a clear path to broaden diagnostic reach across India. This suggests cross-selling opportunities to leverage partner labs for scaled genomic testing and collaborative service offerings in new regions.

In-House Genomics Platform MedGenome’s combination of in-house RNA sequencing, AI-enabled bioinformatics, and proprietary assays positions it to offer end-to-end solutions from sequencing to interpretation. This can be pitched to health systems seeking integrated genomic pipelines and faster turnaround times.

New Test Launches Recent launches such as MetaSeq, RNA sequencing platform for Sarcoma, and CNS Tumor Methylation Classifier indicate a pipeline of innovative assays. Sales opportunities exist to target oncology and diagnostic centers looking for cutting-edge genomic tests and niche biomarkers.

Awareness and Education The #answersthatmatter digital awareness campaign signals a focus on educating clinicians and patients about genetic testing. This creates openings for educational partnerships, sponsored clinical events, and direct outreach to drive adoption of genomic diagnostics in new geographies.